OncoMatch/Clinical Trials/NCT06696768
Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
Is NCT06696768 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies multiple treatments for metastatic colorectal adenocarcinoma.
Treatment: Bevacizumab · Emavusertib · Fluorouracil · Leucovorin Calcium · Oxaliplatin — This phase I trial studies the side effects and best dose of CA-4948 when given together with fluorouracil, leucovorin, oxaliplatin (FOLFOX) plus bevacizumab in treating patients with colorectal cancer that has spread from where it first started (primary site) to other places in the body (metastatic). CA-4948 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The chemotherapy drugs used in FOLFOX, fluorouracil and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Leucovorin is used with fluorouracil to treat colorectal cancer. Bevacizumab is in a class of medications called anti-angiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to the tumor. This may slow the growth and spread of the tumor. Giving CA-4948 with FOLFOX plus bevacizumab may be safe, tolerable and/or effective in treating patients with metastatic colorectal cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Other
Cancer type
Colorectal Cancer
Biomarker criteria
Excluded: MSI high-frequency
Patients with high-frequency microsatellite instability (MSI-H)...colorectal cancer at pre-enrollment screening
Excluded: MLH1 loss
Patients with...deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR) colorectal cancer at pre-enrollment screening
Excluded: MSH2 loss
Patients with...deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR) colorectal cancer at pre-enrollment screening
Excluded: MSH6 loss
Patients with...deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR) colorectal cancer at pre-enrollment screening
Excluded: PMS2 loss
Patients with...deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR) colorectal cancer at pre-enrollment screening
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: chemotherapy (FOLFOX, FOLFIRI, FOLFOXIRI, bevacizumab)
Patients who have received prior treatment with any chemotherapy (either in the adjuvant or metastatic setting), including FOLFOX, fluorouracil/leucovorin/irinotecan (FOLFIRI), folinic acid/fluorouracil/oxaliplatin/irinotecan (FOLFOXIRI), or antiangiogenic agents such as bevacizumab and similar agents, are not eligible for this study
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1,500/mcL; Platelets ≥ 75,000/mcL
Kidney function
Estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73 m^2
Liver function
Total bilirubin ≤ 1.5 × institutional ULN; AST/ALT ≤ 3 × institutional ULN; for those with liver metastases, 5 × institutional ULN
Cardiac function
Creatine phosphokinase (CPK) elevation at screening < grade 2 (CPK ≤ 2.5 x ULN); NYHA class II or better; QTcF ≤ 450ms
Absolute neutrophil count ≥ 1,500/mcL; Platelets ≥ 75,000/mcL; Total bilirubin ≤ 1.5 × institutional ULN; AST/ALT ≤ 3 × institutional ULN; for those with liver metastases, 5 × institutional ULN; eGFR ≥ 60 mL/min/1.73 m^2; CPK ≤ 2.5 x ULN; NYHA class II or better; QTcF ≤ 450ms
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UF Health Cancer Institute - Gainesville · Gainesville, Florida
- Memorial Hospital East · Shiloh, Illinois
- University of Kansas Clinical Research Center · Fairway, Kansas
- University of Kansas Cancer Center · Kansas City, Kansas
- University of Kansas Hospital-Indian Creek Campus · Overland Park, Kansas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06696768 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Are patients with MSI alterations eligible?
No. MSI high-frequency is an exclusion criterion.
Are patients with MLH1 alterations eligible?
No. MLH1 loss is an exclusion criterion.
What disease stage is eligible?
Stage III or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages